Vaccines against Mpox: Combating the Threat

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Epidemiology".

Deadline for manuscript submissions: 15 December 2024 | Viewed by 1018

Special Issue Editor


E-Mail
Guest Editor
World Health Organization, Geneva, Switzerland
Interests: emerging viral diseases; virology; epidemiology

Special Issue Information

Dear Colleagues,

Vaccinology dates back to the times when viruses were not known, and the first vaccine was developed to combat smallpox. Since then, our understanding of the host adaptive immune responses to infectious diseases has led to the development of a variety of vaccine platforms and vaccine technologies to prevent morbidity and mortality from a wide range of infectious diseases. Some of these technologies are well established while some others are still under development.

In this Special Issue, we shed light onto the latest advances in the field of vaccines against orthopoxviruses, with focus on mpox, which still causes outbreaks at the global level and has a significant impact, including in children, in endemic settings.

Dr. Lorenzo Subissi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vaccine efficacy
  • monkeypox
  • mpox
  • smallpox
  • immunity
  • surveillance

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 240 KiB  
Article
Factors Related to Mpox-Vaccine Uptake among Men Who Have Sex with Men in Taiwan: Roles of Information Sources and Emotional Problems
by Mei-Feng Huang, Yu-Ping Chang, Chien-Wen Lin and Cheng-Fang Yen
Vaccines 2024, 12(3), 332; https://doi.org/10.3390/vaccines12030332 - 20 Mar 2024
Viewed by 830
Abstract
An mpox outbreak occurred suddenly and rapidly spread worldwide in 2022. Research has demonstrated a link between the sexual behavior of men who have sex with men (MSM) and the contraction of mpox. This study assessed the factors related to mpox-vaccine uptake among [...] Read more.
An mpox outbreak occurred suddenly and rapidly spread worldwide in 2022. Research has demonstrated a link between the sexual behavior of men who have sex with men (MSM) and the contraction of mpox. This study assessed the factors related to mpox-vaccine uptake among MSM in Taiwan, focusing on the roles of information sources and emotional problems. In total, 389 MSM participated in an online survey. Data on the participants’ vaccination statuses; anxiety symptoms, which were assessed using the State–Trait Anxiety Inventory; depressive symptoms, which were assessed using the Center for Epidemiologic Studies Depression Scale; and risk perceptions of contracting mpox were collected. Factors related to mpox-vaccine uptake were examined using a multivariable logistic regression model. The results revealed that MSM who were older (p < 0.001), perceived a higher risk of contracting mpox (p = 0.040), and received mpox information from health-care providers (p < 0.001) were more likely to receive mpox vaccination, whereas MSM who reported a greater severity of depression (p = 0.017) were less likely to receive mpox vaccination. However, age did not moderate the associations of perceiving a higher risk of contracting mpox, receiving mpox information from health-care providers, and depression with having an mpox vaccination. Health-care providers should consider these factors when developing intervention programs for enhancing mpox-vaccine uptake among MSM. Full article
(This article belongs to the Special Issue Vaccines against Mpox: Combating the Threat)
Back to TopTop